DK1192169T3 - C-pyrazol A2A receptor-agonister - Google Patents

C-pyrazol A2A receptor-agonister

Info

Publication number
DK1192169T3
DK1192169T3 DK00943022T DK00943022T DK1192169T3 DK 1192169 T3 DK1192169 T3 DK 1192169T3 DK 00943022 T DK00943022 T DK 00943022T DK 00943022 T DK00943022 T DK 00943022T DK 1192169 T3 DK1192169 T3 DK 1192169T3
Authority
DK
Denmark
Prior art keywords
pyrazole
receptor agonists
agonists
receptor
Prior art date
Application number
DK00943022T
Other languages
Danish (da)
English (en)
Inventor
Jeff A Zablocki
Elfatih O Elzein
Venkata P Palle
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Application granted granted Critical
Publication of DK1192169T3 publication Critical patent/DK1192169T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK00943022T 1999-06-22 2000-06-21 C-pyrazol A2A receptor-agonister DK1192169T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/338,327 US6214807B1 (en) 1999-06-22 1999-06-22 C-pyrazole 2A A receptor agonists
PCT/US2000/017095 WO2000078778A2 (en) 1999-06-22 2000-06-21 C-pyrazole a2a receptor agonists

Publications (1)

Publication Number Publication Date
DK1192169T3 true DK1192169T3 (da) 2003-08-04

Family

ID=23324355

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00943022T DK1192169T3 (da) 1999-06-22 2000-06-21 C-pyrazol A2A receptor-agonister

Country Status (23)

Country Link
US (6) US6214807B1 (de)
EP (1) EP1192169B1 (de)
JP (1) JP4795591B2 (de)
KR (1) KR100511733B1 (de)
CN (1) CN1152041C (de)
AR (1) AR033794A1 (de)
AT (1) ATE240341T1 (de)
AU (1) AU766712B2 (de)
BR (1) BR0011854A (de)
CA (1) CA2375430C (de)
DE (1) DE60002722T2 (de)
DK (1) DK1192169T3 (de)
ES (1) ES2193969T3 (de)
HK (1) HK1044953A1 (de)
IL (2) IL147195A0 (de)
MX (1) MXPA01013350A (de)
NO (1) NO323163B1 (de)
NZ (1) NZ516335A (de)
PT (1) PT1192169E (de)
TR (1) TR200200320T2 (de)
TW (1) TW589321B (de)
WO (1) WO2000078778A2 (de)
ZA (1) ZA200200298B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9914526A (pt) * 1998-10-16 2001-07-03 Pfizer Derivados de adenina
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US20020012946A1 (en) 2000-02-23 2002-01-31 Luiz Belardinelli Method of identifying partial agonists of the A2A receptor
ATE402164T1 (de) * 2001-04-26 2008-08-15 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
US20050059068A1 (en) * 2001-05-23 2005-03-17 Stratagene California Compositions and methods using dendrimer-treated microassays
US7262176B2 (en) * 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
US20030078232A1 (en) * 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
WO2003029264A2 (en) * 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
HUP0402591A2 (hu) 2002-02-15 2005-09-28 Cv Therapeutics, Inc. Polimer bevonat orvosi eszközök számára
US6900244B2 (en) * 2002-05-24 2005-05-31 Pharmacia Corporation Anilino liver X-receptor modulators
BR0311282A (pt) * 2002-05-24 2005-04-19 Pharmacia Corp Moduladores sulfona de receptor-x do fìgado
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US7683037B2 (en) * 2002-07-29 2010-03-23 Gilead Palo Alto, Inc. Myocardial perfusion imaging method
US6914053B2 (en) 2002-09-09 2005-07-05 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
PT2366396E (pt) * 2004-01-27 2013-10-03 Gilead Sciences Inc Imagiologia de perfusão miocárdica utilizando agonistas do receptor de adenosina
TWI346109B (en) * 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
DK1758596T3 (da) * 2004-05-26 2010-07-26 Inotek Pharmaceuticals Corp Purinderivater som adenosin-A1-receptoragonister og fremgangsmåder til anvendelse deraf
EP1778712B1 (de) * 2004-08-02 2013-01-30 University Of Virginia Patent Foundation 2-propynyl-adenosin-analoga mit modifizierten 5'-ribosegruppen mit a2a-agonistenaktivität
US7863253B2 (en) * 2004-09-20 2011-01-04 Inotek Pharmaceuticals Corporation Purine Derivatives and methods of use thereof
JP2008517063A (ja) * 2004-10-20 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシンレセプターアゴニストの使用
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
CA2627319A1 (en) 2005-11-30 2007-06-07 Prakash Jagtap Purine derivatives and methods of use thereof
PL1989214T3 (pl) 2006-02-03 2017-07-31 Gilead Sciences, Inc. Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
KR20080110925A (ko) 2006-04-21 2008-12-19 노파르티스 아게 아데노신 ａ２ａ 수용체 효능제로서 사용하기 위한 퓨린 유도체
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US20070299089A1 (en) * 2006-06-22 2007-12-27 Cv Therapeutics, Inc. Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia
BRPI0713901A2 (pt) * 2006-06-27 2013-01-08 Biovitrum Ab compostos terapÊuticos
EP1889846A1 (de) 2006-07-13 2008-02-20 Novartis AG Purinderivate als A2a Agonisten
BRPI0716174A2 (pt) * 2006-09-01 2013-09-24 Cv Therapeutics Inc mÉtodos e composiÇÕes para aumentar a tolerabilidade de paciente durante mÉtodos de imagem do miocÁrdio.
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
EP1903044A1 (de) * 2006-09-14 2008-03-26 Novartis AG Adenosinderivate als Agonisten des A2A-Rezeptors
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
BRPI0718792A2 (pt) * 2006-11-10 2013-12-03 Novartis Ag Compostos orgânicos
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
CN102164591A (zh) * 2008-09-29 2011-08-24 吉利德科学股份有限公司 速率控制剂和A-2-α受体拮抗剂的组合用于多检测器计算机化断层显像方法
SG10201502588UA (en) 2010-01-11 2015-05-28 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
MX2012010724A (es) 2010-03-26 2012-11-12 Inotek Pharmaceuticals Corp Metodo para reducir la presion intraocular en seres humanos empleando n6-ciclopentiladenosina (cpa), derivados de cpa o profarmacos de los mismos.
JP2011098990A (ja) * 2011-02-21 2011-05-19 Gilead Palo Alto Inc アデノシン受容体作動薬を使用する心筋灌流イメージング方法
US9278991B2 (en) 2012-01-26 2016-03-08 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of [(2R,3S,4R,5R)-5-(6-(cyclopentylamino)-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)} methyl nitrate and processes of preparation thereof
US20150290236A1 (en) * 2012-11-30 2015-10-15 Leiutis Pharmaceuticals Pvt. Ltd. Pharmaceutical compositions of regadenoson
CN105188714A (zh) 2013-03-15 2015-12-23 伊诺泰克制药公司 眼用配制品

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK135130B (da) 1970-12-28 1977-03-07 Takeda Chemical Industries Ltd Analogifremgangsmåde til fremstilling af 2-substituerede adenosinderivater eller syreadditionssalte deraf.
BE787064A (fr) 1971-08-03 1973-02-01 Philips Nv Dispositif magnetique comportant des domaines
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
JPS6299395A (ja) 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5070877A (en) 1988-08-11 1991-12-10 Medco Research, Inc. Novel method of myocardial imaging
DE3831430A1 (de) 1988-09-15 1990-03-22 Bayer Ag Substituierte 4-heterocyclyloximino-pyrazolin-5-one, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
US5270304A (en) 1988-11-15 1993-12-14 Yamasa Shoyu Kabushiki Kaisha Therapeutic 2-alkynyl adenosine agent for ischemic diseases of the heart or brain
ES2077070T3 (es) 1989-06-20 1995-11-16 Yamasa Shoyu Kk Intermedio de sintesis de 2-alquiniladenosina, produccion de dicho intermedio, produccion de 2-alquiniladenosina a partir de dicho intermedio, y derivado de 2-alquiniladenosina estable.
US5032252A (en) 1990-04-27 1991-07-16 Mobil Oil Corporation Process and apparatus for hot catalyst stripping in a bubbling bed catalyst regenerator
US5189027A (en) 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
JP2740362B2 (ja) 1991-02-12 1998-04-15 ヤマサ醤油株式会社 安定な固体状２‐オクチニルアデノシンおよびその製造法
JPH051993A (ja) 1991-06-26 1993-01-08 Ishikawajima Harima Heavy Ind Co Ltd 帯状繊維物の配向性測定装置
JP3053908B2 (ja) 1991-06-28 2000-06-19 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
WO1993025677A1 (en) 1992-06-12 1993-12-23 Garvan Institute Of Medical Research DNA SEQUENCES ENCODING THE HUMAN A1, A2a and A2b ADENOSINE RECEPTORS
EP0601322A3 (de) 1992-10-27 1994-10-12 Nippon Zoki Pharmaceutical Co Adenosindeaminaseinhibitor.
US5877180A (en) 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US5770716A (en) 1997-04-10 1998-06-23 The Perkin-Elmer Corporation Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same
AU7449598A (en) 1997-05-23 1998-12-11 Nippon Shinyaku Co. Ltd. Medicinal composition for prevention or treatment of hepatopathy
EP1014995A4 (de) 1997-06-18 2005-02-16 Aderis Pharmaceuticals Inc Zusammensetzungen und verfahren zur verhütung von restenosis nach wiedergefässbildung
US6026317A (en) 1998-02-06 2000-02-15 Baylor College Of Medicine Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists
EP1011608A4 (de) 1998-06-08 2002-05-15 Epigenesis Pharmaceuticals Inc Zusammensetzung und methode zur prävention und behandlung von herzlungen-und nierenversagen oder schäden die im zusammenhang stehen mit ischämie, endotoxin freisetzung, ards oder hervorgerufen werden durch die gabe bestimmter medikamente
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6368573B1 (en) 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6605597B1 (en) 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6294522B1 (en) 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6552023B2 (en) 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6677336B2 (en) 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US20020012946A1 (en) 2000-02-23 2002-01-31 Luiz Belardinelli Method of identifying partial agonists of the A2A receptor
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6995148B2 (en) 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US6599283B1 (en) 2001-05-04 2003-07-29 Cv Therapeutics, Inc. Method of preventing reperfusion injury
CN1268610C (zh) 2001-05-14 2006-08-09 诺瓦提斯公司 磺酰胺衍生物
US7683037B2 (en) 2002-07-29 2010-03-23 Gilead Palo Alto, Inc. Myocardial perfusion imaging method
US20050020915A1 (en) 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
PT2366396E (pt) 2004-01-27 2013-10-03 Gilead Sciences Inc Imagiologia de perfusão miocárdica utilizando agonistas do receptor de adenosina
JP2008517063A (ja) 2004-10-20 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシンレセプターアゴニストの使用
US20070299089A1 (en) 2006-06-22 2007-12-27 Cv Therapeutics, Inc. Use of A2A Adenosine Receptor Agonists in the Treatment of Ischemia
BRPI0716174A2 (pt) 2006-09-01 2013-09-24 Cv Therapeutics Inc mÉtodos e composiÇÕes para aumentar a tolerabilidade de paciente durante mÉtodos de imagem do miocÁrdio.
JP2011502101A (ja) 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
US20080267861A1 (en) 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging

Also Published As

Publication number Publication date
US7553823B2 (en) 2009-06-30
US6855818B2 (en) 2005-02-15
US20010018428A1 (en) 2001-08-30
US6214807B1 (en) 2001-04-10
IL147195A0 (en) 2002-08-14
US20040198692A1 (en) 2004-10-07
NO20016351L (no) 2002-02-18
AR033794A1 (es) 2004-01-07
KR20020028911A (ko) 2002-04-17
AU766712B2 (en) 2003-10-23
US20070207978A1 (en) 2007-09-06
EP1192169B1 (de) 2003-05-14
DE60002722T2 (de) 2004-04-08
CA2375430C (en) 2006-03-14
TW589321B (en) 2004-06-01
NO323163B1 (no) 2007-01-08
ZA200200298B (en) 2003-04-30
WO2000078778A3 (en) 2001-05-10
CN1358189A (zh) 2002-07-10
NZ516335A (en) 2003-10-31
CA2375430A1 (en) 2000-12-28
NO20016351D0 (no) 2001-12-21
TR200200320T2 (tr) 2002-05-21
EP1192169A2 (de) 2002-04-03
PT1192169E (pt) 2003-09-30
ATE240341T1 (de) 2003-05-15
US20100081810A1 (en) 2010-04-01
CN1152041C (zh) 2004-06-02
US6770634B1 (en) 2004-08-03
JP4795591B2 (ja) 2011-10-19
ES2193969T3 (es) 2003-11-16
IL147195A (en) 2007-10-31
DE60002722D1 (de) 2003-06-18
AU5755800A (en) 2001-01-09
WO2000078778A2 (en) 2000-12-28
HK1044953A1 (zh) 2002-11-08
US7109180B2 (en) 2006-09-19
MXPA01013350A (es) 2002-07-09
KR100511733B1 (ko) 2005-08-31
JP2003506460A (ja) 2003-02-18
BR0011854A (pt) 2002-06-11

Similar Documents

Publication Publication Date Title
ATE256141T1 (de) N-pyrazol a2a rezeptor agonisten
ATE240341T1 (de) C-pyrazol a2a rezeptor agonisten
PT1192170E (pt) Agonistas de receptor a2a de propargilfenileter
DE60026861D1 (de) Purin-derivate
DE60002356D1 (de) Purin-derivate
EE200100681A (et) Puriinderivaadid
NO20013997L (no) Reseptoranalyse
AU2001247227A1 (en) 2-thioether a2a receptor agonists
ID30056A (id) Agonis-agonis 5-htif
NO20021295L (no) Nikotinsyreacetylcholin-reseptor
TH109999B (th) นิวคลีโอไซด์
DK1090019T3 (da) Adenosinderivater